Skip to main content
. 2020 Feb 19;20:100282. doi: 10.1016/j.eclinm.2020.100282

Table 2.

Dyspnea assessment, chest auscultation, pulmonary function, and CT scan findings of A(H7N9) survivors in follow-up visits.a

Variable 3-months 6-months 12-months 18-months 64-months
Dyspnea assessment
 No. of patients 23 45 34 5 1
 No. of patients with mMRC dyspnea scale ≥1 17 25 18 5 1
 mMRC dyspnea scaleb 1·47 ± 0·80 1·40 ± 0·58 1·16 ± 0·38 1·00 ± 0·00 1·00 ± 0·00
Chest auscultation findings
 No. of patients 24 40 34 7 3
 Moist rales 3 (12·5) 6 (15·0) 3 (8·8) 0 (0·0) 0 (0·0)
 Wheezes 1 (4·2) 0 (0·0) 0 (0·0) 0 (0·0) 0 (0·0)
 Rales and wheezes 1 (4·2) 1 (2·5) 0 (0·0) 0 (0·0) 0 (0·0)
 Coarse breath sounds 1 (4·2) 1 (2·5) 5 (14·7) 0 (0·0) 0 (0·0)
Pulmonary function testing results
 No. of patients 21 38 23 12 3
 Total ventilation dysfunction 12 (57·1) 14 (37·8) 12 (52·1) 5 (41·7) 1 (33·3)
 Obstructive 3 (14·3) 5 (13·5) 4 (17·4) 0 (0·0) 0 (0·0)
 Restrictive 8 (38·1) 7 (18·9) 5 (21·7) 3 (25·0) 1 (33·3)
 Mixed 1 (4·8) 2 (5·4) 3 (13·0) 2 (16·7) 0 (0·0)
 Diffusion dysfunction 9/12 (75·0) 17/27 (62·7) 9/13 (69·2) 4/7 (57·1) 3 (100·0)
Chest CT scans
 No. of patients 18 38 31 12 3
 Ground-glass opacities 12 (66·7) 28 (73·7) 21 (67·7) 8 (66·7) 2 (66·7)
 Nodule 4 (22·2) 2 (5·3) 3 (9·7) 1 (8·3) 0 (0·0)
 Bullous cysts 1 (5·6) 7 (18·4) 7 (22·6) 0 (0·0) 1 (33·3)
 Fibrosis 3 (16·7) 7 (18·4) 6 (19·4) 0 (0·0) 0 (0·0)
 Liner Fibrosis 0 (0·0) 0 (0·0) 3 (9·7) 8 (66·7) 0 (0·0)
 Pleural thickening 2 (11·1) 5 (13·2) 6 (19·4) 3 (25·0) 0 (0·0)
 Pleural effusion 1 (5·6) 2 (5·3) 0 (0·0) 0 (0·0) 0 (0·0)
 Calcification 1 (5·6) 2 (5·3) 1 (3·2) 0 (0·0) 1 (33·3)
 Increased lung marking 1 (5·6) 1 (2·6) 0 (0·0) 5 (41·7) 0 (0·0)
 Parenchymal opacification 0 (0·0) 0 (0·0) 1 (3·2) 1 (8·3) 0 (0·0)
a

Figures are No. (%) unless stated otherwise. If Indicates denominators for testing of fewer cases than full group, will be listed. NA, not applicable.

b

modified Medical Research Council dyspnea scale, mean ± SD, statistical description for mMRC ≥1.

HHS Vulnerability Disclosure